Psychiatry

A new study found that elements such as birth order, low parental education, or low birthweight could increase suicide risk throughout a person’s lifespan.

A new meta-analysis determined DBS is equally useful for patients with Parkinson’s who have related mutations.

Recommended dosage varies, but effectiveness increases with dosage, necessitating conclusive research.

Investigators found that patients receiving cariprazine showed significant improvement in cognitive symptoms compared to patients receiving aripiprazole or placebo therapy.

Allergan announced the FDA approved a New Drug Application for Vraylar for the treatment of depressive episodes associated with bipolar depression.

Steven Adelsheim, MD, discusses what he believes is the need to further recognize that many mental health conditions begin to develop at a young age.

Investigators presented 2 pooled analyses at APA 2019 that explored the safety profile and efficacy of 42mg lumateperone in patients with schizophrenia

Investigators presented the results of a 4-week trial examining the efficacy of SEP-363856 at APA 2019 in San Francisco, CA.

Lori Raney, MD, of Health Management Associates in Colorado, sat down with us at APA 2019 to discuss how clinicians should address the mental health needs of an aging population.

Investigators presented data from a 2-year, open-label study into the efficacy and safety of lurasidone in children 10 to 17 years old at APA 2019.

Godfrey Pearlson, MD, founding director of the division of psychiatry neuroimaging at Johns Hopkins University, discusses the possibility of using neuroimaging to diagnose psychiatric disorders.

Lori Raney, MD, psychiatrist and principal with Health Management Associates in CO, discuss what she believes is the most important discussion topic at APA 2019.

Godfrey Pearlson sat down at APA 2019 to discuss his opinion on what the most significant recent advances in neuropsychiatry have been and how they have impacted practice.

A new study from ATS showed an early symptom of Alzheimer disease is more prevalent in older patients with moderate OSA.

Pear Therapeutics and Novartis presented findings from their study exploring the use of digital therapies in addition to traditional treatment in patients with schizophrenia.

Jonathan Avery, MD, addiction psychiatrist and associate professor of psychiatry, sat down with MD Magazine at APA 2019 to discuss his takeaways and caring for patients with co-occurring mental illness and substance use disorder.

David Kingdon, MD, FRCPsych, professor of mental health care delivery at the University of Southampton, sat down with MD Magazine at APA 2019 to discuss recent advances in psychosis.

Sleep apnea is associated with pulmonary, cardiovascular, psychiatric, neurologic, and weight-related effects. Primary care physicians need to monitor sleep health more.

A study presented at APA 2019 found that esketamine spray to be an effective, fast-acting treatment for people with treatment-resistant depression.

In a study presented at Digestive Disease Week 2019, results indicated the risk of developing Parkinson's disease was 3 times higher in patients who had appendectomies.

Mental health disorders are highly prevalent in certain patients with COPD—and their effect can limit lung function therapy benefit.

Self-reported vision impairment was associated with a greater risk of developing depression and anxiety symptoms in patients 65 and older.

Patients diagnosed with psoriasis face a nearly three-fold greater risk of developing anxiety disorders.

Assaults have become common in emergency departments. Organizers and individuals are calling on caregivers and administrators to collaborate on real solutions.

The investigative drug SEP-363856 has been evidenced in a phase 2 trial to reduced hospitalized patient symptoms and severity.

Esketamine nasal spray is currently relegated to a specific depression patient population, but that may not be for long.

From 2010 to 2017, there was an increase of over 30% in the number of commercially insured children being diagnosed with ADHD.

The selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.

The FDA approved the Monarch electronic Trigeminal Nerve Stimulation based on the findings of a trial involving children aged 7-12 years old.

A new study of 55 million insured young adults in the US found that major depression, type 2 diabetes, and other conditions are becoming more prevalent among them.